2025 Biointron Year-End Networking Party

On Friday, December 12th, 2025, Biointron celebrated the end of the year with a spectacular annual year-end networking party at Boston Marriott Newton in Boston. Bringing together industry professionals, partners, and clients, the event celebrated Biointron’s achievements and hosted two exciting guest speaker presentations.

This party is dedicated to appreciating new and existing clients for their long-standing support and trust, and to looking forward to further collaborations.

The evening began with a speech by Zha Changchun, the CEO of Biointron, who expressed gratitude to all the guests in attendance and conveyed his appreciation for the continued support from our partners and industry colleagues over the years.

This was followed by Lei Shi, PhD, the SVP of R&D at Biointron, who introduced the company and two distinguished guest speakers who shared their insights on innovation and collaboration within the biopharma industry.

Victor Goldmacher, PhD, began his talk describing antibody-drug conjugates as an advancing field. He is the co-founder and Chief Scientific Officer of ImmuVia, Inc., a biotech company developing novel ADC-mimetics.

His career spans over 30 years in research focused on targeted cancer therapeutics, antibody technologies, and the biology of apoptosis. As Head of Cell Biology at ImmunoGen, Inc., he played a pivotal role in the discovery of three FDA-approved anti-cancer biologics (Elahere, Sarclisa, and Kadcyla) as well as the identification of two key cell death suppressors encoded by cytomegalovirus. He later joined Forbius, Inc. as Director of Discovery, where his work on a clinical-stage TGF-beta trap contributed to the company's acquisition by BMS. His presentation touched on:

• Emerging areas of ADC research and development aimed at improving both activity and safety

• How these advances are shaping the requirements for new recombinant antibodies and their derivatives

Seng-Lai (Thomas) Tan, PhD, has over 20 years of combined drug discovery and development experience in both small- and large-molecule therapeutic modalities. He has held increasing leadership roles and led cross-functional and global project teams and external alliances spanning different therapeutic areas, including oncology, autoimmune disease, and infectious disease. Currently, Thomas is the CSO at TFC Therapeutics, a biotech dedicated to developing bispecific antibodies to prevent cancer recurrence and metastasis.

Thomas received his Ph.D. from the Department of Microbiology and Immunology from the University of Washington School of Medicine, and a Mini-MBA in Biopharmaceutical Innovation from Rutgers Center for Management Development. He has over 70 combined publications, book editorials and patents, and has held adjunct faculty position in the Department of Microbiology and Immunology at the Indiana University School of Medicine, Indianapolis. His presentation focused on emerging therapeutic antibody-based modalities for autoimmune, allergic and inflammatory diseases:

• The rising burden of autoimmune diseases affecting millions worldwide

• Why many patients remain resistant to current therapies

• Emerging antibody-based treatments for autoimmune and inflammatory disorders

• Targeting CCR6 as a novel approach to overcome therapeutic resistance

Adding an element of fun and excitement to the evening, a raffle was held with lucky winners walking away with gifts such as iPads, AirPods, and Yeti tumblers!

As the evening concluded, attendees left with a sense of inspiration and optimism. The event reinforced Biointron’s commitment to driving innovation and building meaningful relationships within the biotech community. With exciting plans already underway for 2026, Biointron is poised to continue making an impact in the antibody landscape.

Thank you to everyone who joined us at our Year-End Party. Here’s to another year of breakthroughs, partnerships, and shared success!